XORTX Therapeutics Inc. announce the appointment of Dr. David MacDonald as Chief Technology Officer (CTO). Dr. MacDonald has an over 30-year record of achievement in drug development and leadership in pharma and biotech, achieving critical, value-inflection milestones for those companies. Prior to XORTX, Dr. MacDonald held positions as CTO and later President of MSI Methylation Sciences Inc.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.85 CAD | +5.56% |
|
-4.68% | -1.72% |
May. 17 | XORTX Therapeutics Reprices Warrants Connected With U.S. IPO | MT |
May. 17 | XORTX Therapeutics Brief: Says Repriced Balance of Warrants Issued in Connection with October 2021 US IPO | MT |
![Consensus](/images/consensus_flch.gif)
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-1.72% | 6.04M | |
+15.64% | 121B | |
+18.30% | 112B | |
+4.43% | 22.57B | |
-18.11% | 20.82B | |
-14.70% | 16.3B | |
-16.61% | 16.19B | |
-43.53% | 16.17B | |
+2.16% | 13.17B | |
+24.41% | 11.11B |
- Stock Market
- Equities
- XRTX Stock
- News XORTX Therapeutics Inc.
- XORTX Therapeutics Inc. Appoints Dr. David Macdonald as Chief Technology Officer